Key Points
On a call with investors last week, Danish drugmaker Novo Nordisk shared some teasers about CagriSema, the next generation of semaglutide which is sold under the brand names Ozempic (for diabetes) and Wegovy (for obesity)..
Novo Nordisks executive president of development Martin Holst Lange told the media and investors in London thatlarger trials are likely to show that CagriSemacurrently in the phase III trialwill help users lose up to 25 percent of their weight, adding that the company used data from previous trials to arrive at that number...
On the other hand, semaglutides close competitor tirzepatidea drug by US pharma firm Eli Lilly and Company which is available under brand names Mounjaro (for diabetes) and Zepbound (for obesity)works on another gut hormone, gastric inhibitory polypeptide (GIP), in addition to GLP-1..
In June last year, Eli Lilly released data from a phase II clinical trial of its investigational drug retatrutidea triple agonistin obese patients, which showed that those taking the drug lost up to 24 percent of their body weight in 48 weeks...
A survey conducted by Novo Nordisk, involving over 2,000 people living with obesity in India and 300 healthcare professionals which was released this month, showed that a high number of such people had have anywhere between 1 and 4 comorbidities, such as high blood pressure (32 percent), high cholesterol (27 percent), eating disorder (23 percent) and cardiovascular diseases (19 percent)...
You might be interested in
Half of children given ‘skinny jab’ no longer clinically obese, study finds
18, May, 23Report says giving semaglutide once a week gave ‘historically unprecedented’ results